Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Celestia S. Higano, MD, FACP

Advertisement

Articles by Celestia S. Higano, MD, FACP

Dr. Higano on the State of Immunotherapy in Prostate Cancer

ByCelestia S. Higano, MD, FACP
May 7th 2020

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

ByE. David Crawford, MD,Neal Shore, MD, FACS,Celestia S. Higano, MD, FACP,Anders Neijber, MD, PhD, MBA,Vladimir Yankov, MD
January 3rd 2016

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

Advertisement

Latest Updated Articles

  • Dr. Higano on the State of Immunotherapy in Prostate Cancer
    Dr. Higano on the State of Immunotherapy in Prostate Cancer

    May 7th 2020

  • Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer
    Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

    January 3rd 2016



Advertisement
Advertisement

Trending on OncLive

1

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

2

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

3

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments

4

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

5

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us